SkyCell partners with All Nippon Airways to support Japanese pharma market
At SkyCell, we have expanded our airline partnerships into Japan by partnering with All Nippon Airways (ANA), the country’s largest airline. This collaboration will not only strengthen our support for pharmaceutical customers shipping in and out of Japan, but will also benefit ANA in reaching their own sustainability goals.
Our partnership with ANA will include all the temperature ranges that we have, from -80°C to -60°C, -30°C to -15°C, +2°C to +8°C and +15°C to + 25°C. This gives their customers access to all cold chain internal temperature conditions to facilitate safe, secure and sustainable shipments. With Japan being a pivotal segment in the pharma market, our collaboration with ANA, as well as the utilization of our hybrid container solutions into their cold chain, will ensure the timely arrival of life-saving medicines in the region.
“We at SkyCell are proud to partner with ANA to show our commitment to supporting the Japanese market, and ensure vital medicines reach their destinations fast and without spoilage. When shipping vital pharmaceutical products, there is no room for error. We have created a complete solution that ensures shipments can be safely transported from production to patients around the world.”
ANA and their customers will see why hybrid containers are an ideal solution to issues faced in modern pharma supply chains. Our hybrid containers can maintain stable temperatures without the need for external charging for long periods of time, meaning special infrastructure is not needed to keep the containers at optimal temperatures. By using lightweight, environmentally-friendly material, the technology enables efficiency and reusability. Additionally, they are shock-absorbent and can mitigate any breakage during transport, whilst a double-door system protects the packaging in high-humidity countries.
“We are very glad to announce our new partnership with SkyCell. As the first Japanese IATA CEIV Pharma certified airline since 2017, we have been expanding our capabilities to transport temperature-controlled pharmaceuticals at the global standard and beyond. Especially through this COVID-19 situation, now more than ever, transporting pharmaceuticals safely is a social mission for every process involved in the chain. We want to provide every customers’ needs for various pharmaceuticals including vaccines. The addition of SkyCell to our product lineup is our commitment to our valued customers.”
Furthermore, working towards a sustainable supply chain is also a fundamental part of our partnership. ANA, like many airlines, also has its own sustainability targets and seeks to collaborate with those who have a similar outlook. At SkyCell, sustainability is part of our DNA. We have joined the SBTi, launched our own sustainability report and committed to the Paris Agreement. By partnering with SkyCell, ANA has a collaborator that shares their sustainable vision, and will utilize containers that cut CO2 by half and don’t contribute to landfill waste.
Finally, SkyCell currently has one service center in Japan. This will also support the Japanese market with container availability and bring SkyCell’s hybrid to this essential segment of the pharma industry.
News & Stories
Supporting Vaccine Distribution Across the Globe
In an increasingly complex world, the collaboration between pharma companies and supply chain partners has never been more important, particularly...
SkyCell and Validaide Partner to Revolutionize Pharma Supply Chain
We are excited to announce our partnership with Validaide, a leading platform in lane risk assessment, to improve decision-making and...
SkyCell closes US$116 million Series D
In a significant development, SkyCell has secured a $57 million funding round in partnership with Catalyst, M&G Investments' $6 billion...